| 2016-10-11 10:17:12|
HZNP 10:17 10/11 10/11/16
Horizon Pharma guidance cut only a modest negative, says BMO Capital
BMO Capital analyst Gary Nachman said he views the pre-announced 3Q revenue and EBITDA shortfalls and full-year guidance cut announced by Horizon Pharma as only a modest negative, as he believes some investors were already cautious on guidance and that it was paired with good news about the company spending more to drive long-term growth. The analyst, who still thinks the Actimmune FA Phase 3 data coming in late December can be a major catalyst, keeps his Outperform rating and $30 price target on Horizon shares.